Home>Biology>Biological Molecules>Enzymes>Factors affecting Enzyme Activity
Factors affecting Enzyme Activity
- The activity of an Enzyme is affected by its environmental conditions. Changing these alter the rate of reaction caused by the enzyme. In nature, organisms adjust the conditions of their enzymes to produce an Optimum rate of reaction, where necessary, or they may have enzymes which are adapted to function well in extreme conditions where they live.
- Increasing temperatureincreases the Kinetic Energy that molecules possess. In a fluid, this means that there are more random collisions between molecules per unit time.
- Since enzymes catalyse reactions by randomly colliding with Substrate molecules, increasing temperature increases the rate of reaction, forming more product.
- However, increasing temperature also increases the Vibrational Energy that molecules have, specifically in this case enzyme molecules, which puts strain on the bonds that hold them together.
- As temperature increases, more bonds, especially the weakerHydrogen and Ionic bonds, will break as a result of this strain. Breaking bonds within the enzyme will cause the Active Site to change shape.
- This change in shape means that the Active Site is less Complementary to the shape of the Substrate, so that it is less likely to catalyse the reaction. Eventually, the enzyme will become Denatured and will no longer function.
- As temperature increases, more enzymes' molecules' Active Sites' shapes will be less Complementary to the shape of their Substrate, and more enzymes will be Denatured. This will decrease the rate of reaction.
- In summary, as temperature increases, initially the rate of reaction will increase, because of increased Kinetic Energy. However, the effect of bond breaking will become greater and greater, and the rate of reaction will begin to decrease.
- The temperature at which the maximum rate of reaction occurs is called the enzyme's Optimum Temperature. This is different for different enzymes. Most enzymes in the human body have an Optimum Temperature of around 37.0 °C.
pH - Acidity and Basicity
- pH measures the Acidity and Basicity of a solution. It is a measure of the Hydrogen Ion (H+) concentration, and therefore a good indicator of the Hydroxide Ion (OH-) concentration. It ranges from pH1 to pH14. Lower pH values mean higher H+ concentrations and lower OH- concentrations.
- Acid solutions have pH values below 7, and Basic solutions (alkalis are bases) have pH values above 7. Deionised water is pH7, which is termed 'neutral'.
- H+ and OH- Ions are charged and therefore interfere with Hydrogen and Ionic bonds that hold together an enzyme, since they will be attracted or repelled by the charges created by the bonds. This interference causes a change in shape of the enzyme, and importantly, its Active Site.
- Different enzymes have different Optimum pH values. This is the pH value at which the bonds within them are influenced by H+ and OH- Ions in such a way that the shape of their Active Site is the most Complementary to the shape of their Substrate. At the Optimum pH, the rate of reaction is at an optimum.
- Any change in pHabove or below the Optimum will quickly cause a decrease in the rate of reaction, since more of the enzyme molecules will have Active Sites whose shapes are not (or at least are less) Complementary to the shape of their Substrate.
- Small changes in pH above or below the Optimum do not cause a permanent change to the enzyme, since the bonds can be reformed. However, extreme changes in pH can cause enzymes to Denature and permanently lose their function.
- Enzymes in different locations have different Optimum pH values since their environmental conditions may be different. For example, the enzyme Pepsin functions best at around pH2 and is found in the stomach, which contains Hydrochloric Acid (pH2).
- Changing the Enzyme and Substrateconcentrations affect the rate of reaction of an enzyme-catalysed reaction. Controlling these factors in a cell is one way that an organism regulates its enzyme activity and so its Metabolism.
- Changing the concentration of a substanceonly affects the rate of reaction if it is the limiting factor: that is, it the factor that is stopping a reaction from preceding at a higher rate.
- If it is the limiting factor, increasing concentration will increase the rate of reaction up to a point, after which any increase will not affect the rate of reaction. This is because it will no longer be the limiting factor and another factor will be limiting the maximum rate of reaction.
- As a reaction proceeds, the rate of reaction will decrease, since the Substrate will get used up. The highest rate of reaction, known as the Initial Reaction Rate is the maximum reaction rate for an enzyme in an experimental situation.
- Increasing Substrate Concentration increases the rate of reaction. This is because more substrate molecules will be colliding with enzyme molecules, so more product will be formed.
- However, after a certain concentration, any increase will have no effect on the rate of reaction, since Substrate Concentration will no longer be the limiting factor. The enzymes will effectively become saturated, and will be working at their maximum possible rate.
- Increasing Enzyme Concentration will increase the rate of reaction, as more enzymes will be colliding with substrate molecules.
- However, this too will only have an effect up to a certain concentration, where the Enzyme Concentration is no longer the limiting factor.
1. Lampe C, Bellettato CM, Karabul N, Scarpa M (2013) Mucopolysaccharidoses and other lysosomal storage diseases. Rheum Dis Clin N Am39: 431–455. [PubMed]
2. Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain131: 1969–1978. [PubMed]
3. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem283: 23542–23556. [PMC free article][PubMed]
4. Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, et al. (2010) Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet6: e1001026. [PMC free article][PubMed]
5. Lee S, Sato Y, Nixon RA (2011) Primary lysosomal dysfunction causes cargo-specific deficits of axonal transport leading to Alzheimer-like neuritic dystrophy. Autophagy7: 1562–1563. [PMC free article][PubMed]
6. Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet2: 349–352. [PubMed]
7. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New Engl J Med351: 1972–1977. [PubMed]
8. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Met81: 70–73. [PubMed]
9. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New Engl J Med361: 1651–1661. [PMC free article][PubMed]
10. Ziegler SG, Eblan MJ, Gutti U, Hruska KS, Stubblefield BK, et al. (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Met91: 195–200. [PMC free article][PubMed]
11. Cleeter MWJ, Chau K-Y, Gluck C, Mehta A, Hughes DA, et al. (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int62: 1–7. [PMC free article][PubMed]
12. Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, et al. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell146: 37–52. [PMC free article][PubMed]
13. Gegg ME, Burke D, Heales SJR, Cooper JM, Hardy J, et al. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol72: 455–463. [PMC free article][PubMed]
14. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, et al. (2014) Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain137: 834–848. [PMC free article][PubMed]
15. Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, et al. (2007) Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Movement Disord22: 1481–1484. [PubMed]
16. Parnetti L, Balducci C, Pierguidi L, De Carlo C, Peducci M, et al. (2009) Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiol Dis34: 484–486. [PubMed]
17. van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, et al. (2013) Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Movement Disord28: 747–754. [PubMed]
18. Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, et al. .. (2014) Cerebrospinal Fluid Lysosomal Enzymes and a-Synuclein in Parkinson's disease. Movement Disord In Press. [PMC free article][PubMed]
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosur Ps55: 181–184. [PMC free article][PubMed]
20. R-Core-Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing.
21. Bates D, Maechler M, Bolker B (2011) lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-41.
22. Wayne P (2004) Evaluation of precision performance of quantitative measurement methods, Document EP05-A2. Clinical and Laboratory Standards Institute.
23. Goi G, Fabi A, Lombardo A, Burlina AB, Tiby V, et al. (1987) Stability of enzymes of lysosomal origin in human cerebrospinal fluid. Clin Chim Acta163: 215–224. [PubMed]
24. Beratis NG, Mavrommatis T, Hatiris I, Kavaliotis J, Tsagaropoulou-Stiga H, et al. (1997) Increased activity of lysosomal acid hydrolases in the cell-free cerebrospinal fluid of bacterial meningitis. Pediat Res41: 235–241. [PubMed]
25. Goi G, Caputo D, Bairati C, Lombardo A, Burlina AB, et al. (1993) Enzymes of lysosomal origin in the cerebrospinal fluid and plasma of patients with multiple sclerosis. Eur Neurol33: 1–4. [PubMed]
26. Hultberg B, Olsson JE (1978) Diagnostic value of determinations of lysosomal hydrolases in CSF of patients with neurological diseases. Acta Neurol Scand57: 201–215. [PubMed]
27. Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, et al. (1995) Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem64: 443–446. [PubMed]
28. Lombardo A, Caimi L, Marchesini S, Goi GC, Tettamanti G (1980) Enzymes of lysosomal origin in human plasma and serum: assay conditions and parameters influencing the assay. Clin Chim Acta108: 337–346. [PubMed]
29. Bellettato CM, Scarpa M (2010) Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis33: 347–362. [PubMed]
30. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, et al. (2013) Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson's disease. Cell Metab17: 941–953. [PMC free article][PubMed]
31. Yap TL, Velayati A, Sidransky E, Lee JC (2013) Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab108: 56–64. [PMC free article][PubMed]
32. Armstrong A, Mattsson N, Appelqvist H, Janefjord C, Sandin L, et al. (2014) Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer's Disease. Neuromol Med16: 150–160. [PMC free article][PubMed]
33. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, et al. (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol9: 131–140. [PubMed]
34. Crabtree D, Dodson M, Ouyang X, Boyer-Guittaut M, Liang Q, et al. .. (2013) Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells. J Neurochem In press. [PMC free article][PubMed]
35. Haque A, Banik NL, Ray SK (2008) New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer's disease: cathepsin inhibitors as potential therapeutics. CNS Neurol Disord-Dr7: 270–277. [PubMed]
36. Hartonen M, Mattila I, Ruskeepää A-L, Orešič M, Hyötyläinen T (2013) Characterization of cerebrospinal fluid by comprehensive two-dimensional gas chromatography coupled to time-of-flight mass spectrometry. J Chromatogr A1293: 142–149. [PubMed]
37. Pshezhetsky AV, Ashmarina M (2001) Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. Prog Nucleic Acid Re69: 81–114. [PubMed]
38. Raghavan SS, Topol J, Kolodny EH (1980) Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet32: 158–173. [PMC free article][PubMed]